secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001213900-26-052542
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026
---------------------------------------------------------------------------

- API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.
- All manufacturing payments completed; no additional cash outlays anticipated.
- Supports potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.
- Ongoing Phase 2 trial in advanced ovarian cancer continues enrolling under amended protocol.
- Phase 2 trial of stenoparib + temozolomide for relapsed SCLC recruiting across multiple VA sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026052542/0001213900-26-052542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026052542/ea0289243-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-052542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer